Development of a personalized in-vitro model for dystrophic muscle endogenous repair for drug discovery

Duchenne muscular dystrophy (DMD) is a genetic disorder resulting in progressive muscle degeneration. Satellos Bioscience Inc is developing small molecule drugs that target and modulate DMD muscle stem cells to repair the dystrophic muscle. Despite the advantages of DMD animal models, they are not always predictive of human DMD phenotypes, or their response to drug treatments.